BRCA2 germline pathogenic in advanced EOC: olaparib 1L maintenance (SOLO1) → median PFS n...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-BRCA2-GERMLINE-OVARIAN |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-OVARIAN |
| Sources | SRC-CIVIC SRC-ESMO-OVARIAN-2024 SRC-NCCN-OVARIAN-2025 |
Actionability Facts
| Biomarker | BIO-BRCA1-BRCA2-GERMLINE |
|---|---|
| Variant | BRCA2 germline pathogenic |
| Disease | DIS-OVARIAN |
| ESCAT tier | IA |
| Recommended combinations | olaparib monotherapy maintenance, niraparib monotherapy maintenance, rucaparib monotherapy maintenance, olaparib + bevacizumab (PAOLA-1) |
| Evidence summary | BRCA2 germline pathogenic in advanced EOC: olaparib 1L maintenance (SOLO1) → median PFS not reached vs 13.8 mo placebo at 5y. Niraparib (NOVA), rucaparib (ARIEL3) approved in platinum-sensitive recurrence. ESCAT IA / OncoKB Level 1. |
Notes
Cascade testing mandatory. Includes primary peritoneal and fallopian-tube. BRCA2 carriers also have ~50% lifetime breast cancer risk and elevated pancreatic/prostate risk in carrier relatives.
Used By
No reverse references found in the YAML corpus.